Sugi Predict

Sugi Predict / Compounds / SCHEMBL9686927

SCHEMBL9686927

SCHEMBL9686927

Cc1cc(N)c(Cl)nc1Cl

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CD44 P16070 1/20 0.48
▸ CYP3A4 P08684 4/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ TDP1 Q9NUW8 3/20 0.41
▸ TERT O14746 1/20 0.38
▸ POLB P06746 1/20 0.36
▸ SLC9A1 P19634 1/20 0.36
▸ MPO P05164 1/20 0.36
▸ ALDH1A1 P00352 5/20 0.34
▸ GAA P10253 2/20 0.34
▸ UHRF1 Q96T88 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ NR4A2 P43354 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CASP1 P29466 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30916379 0.83 CD44 (0.46) CD44CYP3A4MAPK1TSHRTDP1
SCHEMBL10373232 0.83 CD44 (0.46) CD44CYP3A4MAPK1TSHRTDP1
SCHEMBL16599622 0.83 CD44 (0.46) CD44CYP3A4MAPK1TSHRTDP1
SCHEMBL20278433 0.83 CD44 (0.46) CD44CYP3A4MAPK1TSHRTDP1
SCHEMBL24496554 0.79 CD44 (0.43) CD44CYP3A4MAPK1TSHRTDP1
SCHEMBL12072960 0.76 CD44 (0.40) CD44CYP3A4MAPK1TSHRTDP1
SCHEMBL29959988 0.75 TDP1 (0.41) CD44CYP3A4MAPK1TSHRTDP1
SCHEMBL20856165 0.75 TDP1 (0.41) CD44CYP3A4MAPK1TSHRTDP1
SCHEMBL2561658 0.74 ALDH1A1 (0.35) CD44CYP3A4MAPK1TSHRTDP1
SCHEMBL11003082 0.74 GAA (0.50) CD44CYP3A4MAPK1TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0187376-A2 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids BAYER AG (DE) 1986-07-16 — — EP claimed
EP-4652168-A1 5-AMINO-1H-PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2025-11-26 — — EP disclosed
US-20250340554-A1 5-Amino-1H-Pyrrolo[3,2-b]Pyridine-2-Carboxamide Derivatives as MTA-Cooperative Inhibitors of PRMT5 BEONE MEDICINES I GMBH (CH) 2025-11-06 — — US disclosed
WO-2024153230-A1 5-AMINO-1H-PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE, LTD. (KY) 2024-07-25 — — WO disclosed
EP-4364804-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica NV (BE) 2024-05-08 — — EP disclosed
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2024-02-13 — — US disclosed
EP-3833662-B1 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2024-01-17 — — EP disclosed
US-20220315604-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2022-10-06 — — US disclosed
US-11427601-B1 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2022-08-30 — — US disclosed
EP-3833662-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica N.V. (BE) 2021-06-16 — — EP disclosed
CN-112930347-A Inhibitors of KEAP1-Nrf2 protein-protein interactions 詹森药业有限公司 2021-06-08 — — CN disclosed
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2021-03-16 — — US disclosed
WO-2020041169-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-27 — — WO disclosed
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-20 — — US disclosed
EP-0187376-B1 6,7-DISUBSTITUTED 1-CYCLOPROPYL-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACIDS BAYER AG (DE) 1992-05-13 — — EP disclosed
EP-0333020-A2 Process for the preparation of substituted pyridines ABBOTT LABORATORIES (US) 1989-09-20 — — EP disclosed
US-4840954-A BACTERICIDE BAYER AKTIENGESELLSCHAFT (DE) 1989-06-20 — — US disclosed
EP-0187376-A2 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids BAYER AG (DE) 1986-07-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315604-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 CD44 2258/4885CYP3A4 1999/4885MAPK1 1279/4885
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 CD44 2258/4885CYP3A4 1999/4885MAPK1 1279/4885
US-11427601-B1 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 CD44 2258/4885CYP3A4 1999/4885MAPK1 1279/4885
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 CD44 2258/4885CYP3A4 1999/4885MAPK1 1279/4885
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 CD44 2258/4885CYP3A4 1999/4885MAPK1 1279/4885
US-20250340554-A1 5-Amino-1H-Pyrrolo[3,2-b]Pyridine-2-Carboxamide Derivatives as MTA-Cooperative Inhibitors of PRMT5 PRMT5, PRMT1, PRMT3 CD44 4701/4885CYP3A4 3974/4885MAPK1 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.